MorphoSys and GlaxoSmithKline Partner in Antibody Pact - - BioPharm International

ADVERTISEMENT

MorphoSys and GlaxoSmithKline Partner in Antibody Pact


MorphoSys has formed a global agreement with GlaxoSmithKline (GSK) to develop and commercialize MOR103, MorphoSys's proprietary HuCAL-derived antibody for treating mild to moderate rheumatoid arthritis. Under the agreement, GSK assumes responsibility for all subsequent development and commercialization of MOR103. MorphoSys receives an immediate upfront payment of EUR 22.5 million ($29.4 million) and up to EUR 423 million ($552 million), in addition to tiered, double-digit royalties on net sales, based on achieving certain developmental, regulatory, commercial and sales-based milestones.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
PDA Announces Technical Report on Drug Shortages
September 9, 2014
Infinity and AbbVie Collaborate to Develop Oncology Drug
September 5, 2014
Merck KGaA Breaks Ground on Facility in China
September 5, 2014
DPT Laboratories Acquires Media Pharmaceuticals' Lakewood Facilities
September 5, 2014
Author Guidelines

Click here